On September 21, 2023, the company submitted a production application for cefradine and avibactam sodium for injection.

Ceftazidime/Avibactam is a new enzyme inhibitor mixture composed of ceftazidime and avibactam. Ceftazidime is a third-generation cephalosporin (β-lactam) that binds to penicillin-binding proteins in bacterial cells. It binds to inhibit cell wall synthesis, thereby killing bacteria; avibactam is a new type of β-lactamase inhibitor that forms a covalent conjugate through the amide bond and the nucleophilic attacking β-lactamase serine ring opening, and is stabilized The enzyme-inhibitor complex can effectively prevent ceftazidime from being hydrolyzed and inactivated by β-lactamase [carbapenemase (KPC)], and protect the antibacterial activity of ceftazidime against a variety of KPC-producing Enterobacteriaceae strains. Ceftazidime/avibactam is mainly used to treat complicated intra-abdominal infections and HAP caused by Gram-negative bacteria such as Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, Proteus mirabilis and Pseudomonas aeruginosa. (hospital-acquired pneumonia) and VAP (ventilator-associated pneumonia).

Genchain's early product portfolio mainly revolves around the new national drug reform policy. It is expected that nearly 30 of the company's more than 40 projects are expected to catch up with the country's first batch of centralized procurement. Through centralized procurement, Genchain can become one of the main supplier with a large share of my country's medical institutions market in the next five years. In order to achieve sustainable development, the company is currently planning to introduce international elements. On the one hand, it will graft international resources in raw material procurement, research and development and other aspects, enter the field of complex generic drug development, and selectively intervene in the blue ocean track. On the one hand, it explores the licensing introduction path, introduces innovative drugs from Europe and other regions in a timely manner, and uses a differentiated strategy to enhance Genchain's competitiveness in the domestic pharmaceutical market. At the same time, relying on Hainan's location advantages and free trade zone policy support, we are targeting international markets such as Southeast Asia and Europe in product development and design, product clinical layout, production system and quality system construction, market expansion, etc., becoming a globally competitive industry. and brand reputation of pharmaceutical companies.